1. Signaling Pathways
  2. Immunology/Inflammation
    Metabolic Enzyme/Protease
  3. Arginase
  4. Arginase Inhibitor

Arginase Inhibitor

Arginase Inhibitors (15):

Cat. No. Product Name Effect Purity
  • HY-112885B
    nor-NOHA monoacetate
    Inhibitor 99.96%
    nor-NOHA monoacetate is a selective and reversible arginase inhibitor. nor-NOHA monoacetate induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA monoacetate has anti-leukemic activity. nor-NOHA monoacetate can used in study of endothelial dysfunction, immunosuppression and metabolism.
  • HY-101979A
    Numidargistat dihydrochloride
    Inhibitor 98.65%
    Numidargistat (CB-1158) dihydrochloride is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent.
  • HY-19548A
    BEC hydrochloride
    Inhibitor ≥98.0%
    BEC hydrochloride is a slow-binding and competitive Arginase II inhibitor with Ki of 0.31 μM and 30 nM at pH 7.5 and pH 9.5, respectively.
  • HY-15775
    Arginase inhibitor 1
    Inhibitor ≥98.0%
    Arginase inhibitor 1 is a potent inhibitor of human arginases I and II with IC50s of 223 and 509 nM, respectively.
  • HY-W062216
    2-Aminoimidazole
    Inhibitor
    2-Aminoimidazole is a potent antibiofilm agent that can be used as an adjuvant to antimicrobial. 2-aminoimidazoles disrupts the ability of bacteria to protect themselves by inhibiting biofilm formation and genetically-encoded antibiotic resistance traits. 2-Aminoimidazole is also a weak noncompetitive inhibitor of human arginase I with a Ki of 3.6 mM.
  • HY-155108
    OATD-02
    Inhibitor
    OATD-02 is an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and 2. OATD-02 is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 abolishes tumor immunosuppression induced by both arginases. OATD-02 can be used for melanoma study.
  • HY-161061
    Arginase inhibitor 7
    Inhibitor
    Arginase inhibitor 7 (compound A17) is an arginase (ARG1) inhibitor, with an IC50 of 0.16 μM. Arginase inhibitor 7 has high oral bioavailability.
  • HY-101979
    Numidargistat
    Inhibitor ≥98.0%
    Numidargistat (CB-1158) is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent.
  • HY-N2237
    Piceatannol 3'-O-glucoside
    Inhibitor 99.87%
    Piceatannol 3'-O-glucoside, an active component of Rhubarb, activates endothelial nitric oxide (NO) synthase through inhibition of arginase activity with IC50s of 11.22 µM and 11.06 µM against arginase I and arginase II, respectively.
  • HY-112868B
    ABH hydrochloride
    Inhibitor
    ABH (hydrochloride) is a potent arginase inhibitor. ABH (hydrochloride) can be used for researching anti-inflammation.
  • HY-W010510
    DL-Norvaline
    Inhibitor ≥98.0%
    DL-Norvaline, a derivative of L-norvaline, L-norvaline is a non-competitive inhibitor of arginase.
  • HY-112885A
    nor-NOHA acetate
    Inhibitor ≥99.0%
    nor-NOHA acetate (Nω-Hydroxy-nor-L-arginine acetate) is a specific and reversible arginase inhibitor, induces apoptosis in ARG2-expressing cells under hypoxia but not normoxia. Anti-leukemic activity, effective in endothelial dysfunction, immunosuppression and metabolism.
  • HY-145331A
    ARG1-IN-1 hydrochloride
    Inhibitor
    ARG1-IN-1 (example 1) hydrochloride is a human arginase 1 inhibitor with an IC50 of 29 nM.
  • HY-145331
    ARG1-IN-1
    Inhibitor
    ARG1-IN-1 (example 1) is a human arginase 1 inhibitor with an IC50 of 29 nM.
  • HY-112885C
    nor-NOHA dihydrochloride
    Inhibitor 98.85%
    nor-NOHA dihydrochloride is a selective and reversible arginase inhibitor. nor-NOHA dihydrochloride induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA dihydrochloride has anti-leukemic activity. nor-NOHA dihydrochloride can used in study endothelial dysfunction, immunosuppression and metabolism.